Summary of findings for education vs control
Adverse events · people with Parkinson's disease
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
37 questions · 37 findings · 20 reviews · Movement Disorders
No studies found 2 · 5.4%GRADE not reported 0 · 0%Very low 14 · 37.8%Low 10 · 27%Moderate 8 · 21.6%High 3 · 8.1%
Summary of findings for exercise plus education vs control
Adverse events · people with Parkinson's disease
1 finding from 1 review
- no estimate extracted2 studies · 343 participantsVery low
Exercise vs control
Adverse events · people with Parkinson's disease
1 finding from 1 review
- no estimate extracted8 studies · 1242 participantsVery low
Botulinum toxin type A vs anticholinergics
Adverse events · cervical dystonia
1 finding from 1 review
- Botulinum toxin type A versus anticholinergics for cervical dystonia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Summary of findings: Iron vs placebo
Adverse events · patients with restless legs syndrome
Iron showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.48 [0.97, 2.25]6 studies · 298 participantsModerate
Deep brain stimulation vs sham stimulation
Adverse events · adults with dystonia (generalised, segmental, and cervical)
It is very uncertain whether deep brain stimulation changes adverse Events compared with sham stimulation (very low certainty).
1 finding from 1 review
- RR 1.58 [0.98, 2.54]2 studies · 102 participantsVery low
Botulinum toxin vs placebo
Adverse events · Tourette's syndrome with motor and phonic tics
1 finding from 1 review
- Botulinum toxin for motor and phonic tics in Tourette's syndrome 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 18 participantsVery low
Opioids vs placebo
Adverse events · RLS
Opioids may leads to higher adverse Events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.22 [1.07, 1.39]1 study · 304 participantsLow
Virtual reality vs passive intervention (short term)
Adverse events · rehabilitation in Parkinson's disease
1 finding from 1 review
- no estimate extracted1 study · 24 participantsVery low
Intervention not reported
Adverse events ( · people with essential tremor
1 finding from 1 review
- no estimate extracted1 study · 221 participantsLow
GLP‐1 agonists vs placebo
Serious adverse events · adults with Parkinson's disease
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
GLP‐1 agonists vs no treatment
Serious adverse events. · adults with Parkinson's disease
It is very uncertain whether GLP‐1 receptor agonists changes serious adverse events. compared with no treatment (very low certainty).
1 finding from 1 review
- RR 1.6 [0.4, 6.32]1 study · 44 participantsVery low
Virtual reality vs active intervention (short term)
Number of adverse events · rehabilitation in Parkinson's disease
1 finding from 1 review
- no estimate extracted4 studies · 115 participantsLow
Botulinum neurotoxin B vs placebo
Adverse effects: dry mouth · adults with cervical dystonia
Botulinum neurotoxin B leads to higher adverse events: dry mouth compared with placebo (high certainty).
1 finding from 1 review
- RR 7.65 [2.75, 21.32]4 studies · 438 participantsHigh
Botulinum neurotoxin B vs placebo
Dysphagia · adults with cervical dystonia
Botulinum neurotoxin B leads to higher adverse events: dysphagia compared with placebo (high certainty).
1 finding from 1 review
- RR 6.78 [2.42, 19.05]4 studies · 438 participantsHigh
GLP‐1 agonists vs placebo
Adverse events ‐ weight loss · adults with Parkinson's disease
GLP‐1 receptor agonists showed no clear difference in adverse events ‐ weight loss compared with placebo (low certainty).
1 finding from 1 review
- RR 1.25 [0.89, 1.76]1 study · 60 participantsLow
GLP‐1 agonists vs no treatment
Adverse events ‐ weight loss · adults with Parkinson's disease
1 finding from 1 review
- no estimate extracted1 study · 44 participantsVery low
Summary of findings: levodopa vs placebo
Dropouts due to adverse events · patients with restless legs syndrome
Summary of findings: levodopa showed no clear difference in dropouts due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- OR 0.73 [0.05, 11.34]6 studies · 109 participantsModerate
Intervention not reported
Withdrawals due to adverse events · patients with essential tremor
1 finding from 1 review
- no estimate extracted1 study · 24 participantsVery low
Zonisamide vs placebo
Adverse events Number of adverse events · patients with essential tremor
It is very uncertain whether zonisamide changes adverse events Number of adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RD 0.6 [0.28, 0.92]1 study · 20 participantsVery low